10th September 2019
Nuformix plc
("Nuformix" or "the Group"),
Result of Annual General Meeting
The Annual General Meeting of Nuformix plc was held on 10th September 2019 at 1.00pm, at the offices of Shakespeare Martineau LLP, 60 Gracechurch Street,
As announced this morning resolution 7 was withdrawn from the meeting. The Directors of the Company wish to announce that all other resolutions put to shareholders were duly passed and approved on a show of hands at the meeting. The results of the proxy voting position received in advance of the meeting are reported below:
|
|
Resolution |
Ordinary/ Special |
For |
|
Against |
|
Total votes cast |
|
|
|
|
No. of votes |
% |
No. of votes |
% |
|
|
1 |
To receive the annual report and accounts for the year ended 31 March 2019
|
Ordinary |
121,471,999 |
100 |
0 |
0 |
121,471,999 |
|
2 |
To approve the Annual Report on Remuneration
|
Ordinary |
121,413,979
|
100 |
0 |
0 |
121,413,979
|
|
3 |
To re-appoint David Tapolczay as a director
|
Ordinary |
121,465,547
|
100 |
0 |
0 |
121,465,547
|
|
4 |
To re-appoint Daniel Gooding as a director
|
Ordinary |
121,471,999
|
100 |
0 |
0 |
121,471,999
|
|
5 |
To re-appoint Joanne Holland as a director
|
Ordinary |
121,465,547
|
100 |
0 |
0 |
121,465,547
|
|
6 |
To re-appoint John Lidgey as a director
|
Ordinary |
83,841,906
|
99.85 |
123,641
|
0.15 |
83,965,547
|
|
7 |
To re-appoint Kirk Siderman-Wolter as a director
|
Ordinary |
Withdrawn |
|
|
|
|
|
8 |
To re-Christopher Blackwell as a director
|
Ordinary |
121,465,547
|
100 |
0 |
0 |
121,465,547
|
|
9 |
To re-appoint haysmacintyre as auditor
|
Ordinary |
121,465,547
|
100 |
0 |
0 |
121,465,547
|
|
10 |
To authorise the Directors to determine the auditor's fees.
|
Ordinary |
121,465,547
|
100 |
0 |
0 |
121,465,547
|
|
11 |
To authorise the Directors to allot shares.
|
Ordinary |
121,471,999
|
100 |
0 |
0 |
121,471,999
|
|
12 |
To authorise the Directors to disapply pre-emption rights.
|
Special |
121,465,547
|
100 |
0 |
0 |
121,465,547
|
|
13 |
To authorise the Company to purchase its own shares.
|
Special |
121,471,999
|
100 |
0 |
0 |
121,471,999
|
|
14 |
To authorise calling of a general meeting on 14 clear days' notice.
|
Special |
121,471,999
|
100 |
0 |
0 |
121,471,999
|
A vote withheld is not a vote in law and is not counted in the calculation of votes validly cast for or against a resolution.
The Company's issued share capital is 469,466,512 ordinary shares of
Enquiries:
|
Nuformix plc Dr Dan Gooding, Chief Executive Officer |
+44 (0)1223 423667
|
|
Optimum Strategic Communications Mary Clark, Supriya Mathur Email: nuformix@optimumcomms.com |
+44 (0) 203 950 9144 |
About Nuformix plc: www.nuformix.com
Nuformix is a pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs. Nuformix's risk-mitigated development strategy has resulted in a pipeline of discoveries through which it has developed and patented novel cocrystal forms of approved small molecules.
Nuformix has created an IP portfolio of granted patents covering cocrystal forms of five small molecule drugs. Nuformix is targeting high-value unmet needs with its lead programmes in oncology supportive care: NXP001 and fibrosis: NXP002.
Nuformix was established in
Nuformix plc shares are traded on the London Stock Exchange's Official List under the ticker: NFX.L.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the